Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Lobaplatin

Alternative Names: lobaplatin
Latest Update: 2024-12-03
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: p53 Inducer

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sun Yat-sen University
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Gastrointestinal Cancer

Phase 3: Esophageal Cancer|Hepatocellular Carcinoma|Osteosarcoma|Colorectal Cancer|Liver Cancer

Phase 2: Colorectal Cancer|Small Cell Lung Cancer|Head and Neck Cancer|Nasopharyngeal Cancer|Squamous Cell Carcinoma|Osteosarcoma|Breast Cancer|Gastrointestinal Cancer|Triple Negative Breast Cancer

Phase 1: Bone Cancer|Nasopharyngeal Diseases|Bone Marrow Diseases|Non-Small-Cell Lung Cancer|Intestinal Diseases|Breast Cancer|Gastrointestinal Cancer|Nasopharyngeal Cancer|Breast Diseases|Liver Cancer|Kidney Diseases|Small Cell Lung Cancer|Kidney Cancer|Head and Neck Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ChiCTR2400094426

N/A

Recruiting

Triple Negative Breast Cancer

2027-10-31

2022-KY062

P2

Enrolling by invitation

Nasopharyngeal Cancer

2026-12-31

2022-KY-298-01

P3

Recruiting

Hepatocellular Carcinoma

2026-01-01

2022-KY-277-01

P3

Recruiting

Liver Cancer

2026-01-01

Recent News Events

Date

Type

Title

04/17/2024

PubMed

 A Clinical Study of Intraoperative Perfusion Chemotherapy in Gastric Cancer: A Prospective Cohort Study.

04/11/2024

PubMed

 Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial.

04/09/2024

PubMed

 Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: A study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01).

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions